ArticleLancet regional health. Americas2025

Effectiveness of nirsevimab among infants in their first RSV season in the United States, October 2023-March 2024: a test-negative design analysis.

Amanda B Payne et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.